Hong Kong
· Delayed Price · Currency is HKD Transcenta Holding Company Description
Transcenta Holding Limited, a clinical stage biopharmaceutical company, engages in the discovery, research, development, manufacture, and commercialization of various drugs for unmet medical needs in the People’s Republic of China and the United States.
It develops MSB2311, a humanized PD-L1 monoclonal antibody (mAb) candidate for TMB-H solid tumors; TST001, a humanized claudin 18.2 mAb candidate for solid tumors, such as gastric and gastroesophageal cancer; TST808, a humanized antibody regulating B/plasma cell; TST005, a PD-L1/TGF-β bi-functional protein candidate for solid tumors; TST002 (Blosozumab), a humanized sclerostin mAb candidate for osteoporosis; and TST004, a humanized mannan-binding lectin serine protease 2 (MASP 2) mAb candidate for IgA kidney diseases.
It also develops TST010, an antibody candidate targeting regulatory T cells to enhance T cell mediated tumor killing; TST003, a regulatory protein expressed by stromal cells and tumor cells, including colon, prostate, gastric, lung, esophageal, pancreatic, and breast cancers; TST006, a bi-specific claudin 18.2/PD-L1 antibody for solid tumors; TST008, a bi-functional antibody for MASP-2 and BAFF for autoimmune diseases; MSB0254, a humanized VEGFR-2 mAb candidate for solid tumors; TST012 and TST013, an ADC candidate targeting biomarker expressing gastric cancer and other solid tumors; TST801, a bifunctional fusion protein for autoimmune diseases; and TST105, a bispecific ADC candidate targeting FGFR2b and an undisclosed tumor.
The company has a partnership and collaboration agreements with Bristol Myers Squibb and Eli Lilly & Company; research collaboration with Alebund Pharmaceuticals, Dana Farber Cancer Institute, and John Hopkins University.
The company was formerly known as MabSpace International Limited and changed its name to Transcenta Holding Limited in June 2019.
Transcenta Holding Limited was incorporated in 2010 and is headquartered in Suzhou, the People’s Republic of China.
| Country | Cayman Islands |
| Founded | 2010 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 184 |
| CEO | Xueming Qian |
Contact Details
Address: B6-501, 218 Xinghu Street Suzhou, 215123 China | |
| Phone | 86 12 6707 9200 |
| Website | transcenta.com |
Stock Details
| Ticker Symbol | 6628 |
| Exchange | Hong Kong Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | CNY |
| ISIN Number | KYG9005B1041 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Li Xu M.D. | Head of CDx, Member of Scientific Advisory Board, Strategic Advisor to Chief Executive Officer and Non-Executive Director |
| Dr. Xueming Qian Ph.D. | Executive Chairman and Chief Executive Officer |
| Weiwei Liang M.B.A. | Acting Chief Financial Officer, Senior Vice President of Business Development Transaction and Corporate Strategy |
| Dr. Christopher Hwang Ph.D. | Executive Vice President of Process Development and Chief Technology Officer |
| Wei Wang | Vice President of Investor Relations and Capital Markets Department and Secretary to the Board |
| Dr. Yi Gu Ph.D. | Senior Vice President and Head of Research |
| Dr. Charlie Qi M.D. | Senior Vice President of Global Clinical Development |
| Dr. Wen-I Chang Ph.D. | Senior Vice President of Oncology Franchise Strategy |
| Dr. Caroline Germa M.D., Ph.D. | Executive Vice President of Global Medicine Development and Chief Medical Officer |
| Fan Zhang | SVice President of Process Development |